Literature DB >> 18511749

A percentage analysis of the telomere length in Parkinson's disease patients.

Jing Zhi Guan1, Toyoki Maeda, Masahiro Sugano, Jun-ichi Oyama, Yoshihiro Higuchi, Tomokazu Suzuki, Naoki Makino.   

Abstract

Telomeres are the repeated sequences at the chromosome ends which undergo shortening with cell division. The telomere shortening of the peripheral leukocytes is also facilitated by enhanced oxidative stress in various kinds of disease including ischemic heart disease, diabetes mellitus, apoplexy, and Alzheimer's disease. Telomere shortening in Parkinson's disease (PD) has not yet been reported. The pathogenesis for PD is also regarded to be associated with oxidative stress. We investigated 28 Japanese male PD patients ages 47-69. Although we could not find a statistical difference in the mean telomere length of peripheral leukocytes between the PD patients and the control participants, we found the mean telomere lengths to be shorter than 5 kb in only the PD patients and a significant PD-associated decrease in the telomeres with a length ranging from 23.1 to 9.4 kb in the patients in their 50s and 60s. These observations suggest that telomere shortening is accelerated in PD patients in comparison to the normal population.

Entities:  

Mesh:

Year:  2008        PMID: 18511749     DOI: 10.1093/gerona/63.5.467

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  27 in total

1.  The Subtelomere of Short Telomeres is Hypermethylated in Alzheimer's Disease.

Authors:  Jing-Zhi Guan; Wei-Ping Guan; Toyoki Maeda; Naoki Makino
Journal:  Aging Dis       Date:  2011-12-10       Impact factor: 6.745

2.  Age-related changes in subtelomeric methylation in the normal Japanese population.

Authors:  Toyoki Maeda; Jing Zhi Guan; Jun-ichi Oyama; Yoshihiro Higuchi; Naoki Makino
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-17       Impact factor: 6.053

3.  Telomere length and Parkinson's disease in men: a nested case-control study.

Authors:  M Schürks; J Buring; R Dushkes; J M Gaziano; R Y L Zee; T Kurth
Journal:  Eur J Neurol       Date:  2013-09-07       Impact factor: 6.089

Review 4.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

5.  High plasma folate is negatively associated with leukocyte telomere length in Framingham Offspring cohort.

Authors:  Ligi Paul; Paul F Jacques; Abraham Aviv; Ramachandran S Vasan; Ralph B D'Agostino; Daniel Levy; Jacob Selhub
Journal:  Eur J Nutr       Date:  2014-05-03       Impact factor: 5.614

6.  The correlation between the clinical laboratory data and the telomere length in peripheral blood leukocytes of Japanese female patients with hypertension.

Authors:  T Maeda; J-I Oyama; M Sasaki; T Arima; N Makino
Journal:  J Nutr Health Aging       Date:  2011-03       Impact factor: 4.075

7.  The correlation between the telomeric parameters and the clinical laboratory data in the patients with brain infarct and metabolic disorders.

Authors:  T Maeda; J-I Oyama; Y Higuchi; T Arima; K Mimori; N Makino
Journal:  J Nutr Health Aging       Date:  2010-11       Impact factor: 4.075

8.  Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease.

Authors:  G Watfa; C Dragonas; T Brosche; R Dittrich; C C Sieber; C Alecu; A Benetos; R Nzietchueng
Journal:  J Nutr Health Aging       Date:  2011-04       Impact factor: 4.075

9.  Telomere length in Parkinson's disease: A meta-analysis.

Authors:  Diego A Forero; Yeimy González-Giraldo; Catalina López-Quintero; Luis J Castro-Vega; George E Barreto; George Perry
Journal:  Exp Gerontol       Date:  2016-01-07       Impact factor: 4.032

Review 10.  Telomere shortening in neurological disorders: an abundance of unanswered questions.

Authors:  Erez Eitan; Emmette R Hutchison; Mark P Mattson
Journal:  Trends Neurosci       Date:  2014-03-31       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.